ELISA kit for Homo sapiens (Human) Preferentially Expressed Antigen In Melanoma (PRAME)
MAPE; OIP4; CT130; Cancer/Testis Antigen 130; Opa-interacting protein 4; Melanoma antigen preferentially expressed in tumors
- 96T (KEP419Hu) US$ 700
Description: Preferentially Expressed Antigen In Melanoma (PRAME)
Organism Species: Homo sapiens (Human)
Sample Type: tissue homogenates, cell lysates, cell culture supernates and other biological fluids
Test Method: Double-antibody Sandwich
Assay Length: 3h
Detection Range: 0.156-10ng/mL
Sensitivity: The minimum detectable dose of this kit is typically less than 0.061ng/mL.
Specifity: This assay has high sensitivity and excellent specificity for detection of Preferentially Expressed Antigen In Melanoma (PRAME). No significant cross-reactivity or interference between Preferentially Expressed Antigen In Melanoma (PRAME) and analogues was observed.
Typical Standard Curve:
Results demonstration:
Stability: The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Storage: Store at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for one year without detectable loss of activity. Avoid repeated freeze-thaw cycles.
Notes: For In vitro laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Recovery
Matrices listed below were spiked with certain level of recombinant Preferentially Expressed Antigen In Melanoma (PRAME) and the recovery rates were calculated by comparing the measured value to the expected amount of Preferentially Expressed Antigen In Melanoma (PRAME) in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 78-96 | 84 |
| EDTA plasma(n=5) | 78-94 | 90 |
| heparin plasma(n=5) | 78-97 | 84 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Preferentially Expressed Antigen In Melanoma (PRAME) were tested 24 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Preferentially Expressed Antigen In Melanoma (PRAME) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Preferentially Expressed Antigen In Melanoma (PRAME) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 95%-100% | 95-103% | 98-104% | 99-105% |
| EDTA plasma(n=5) | 90-101% | 95-101% | 82-93% | 87-94% |
| heparin plasma(n=5) | 95-105% | 85-96% | 97-96% | 89-101% |
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
|---|---|---|---|
| Pre-coated, ready to use 96-well strip plate | 1 | Plate sealer for 96 wells | 4 |
| Standard | 2 | Standard Diluent | 1×20mL |
| Detection Reagent A | 1×120µL | Assay Diluent A | 1×12mL |
| Detection Reagent B | 1×120µL | Assay Diluent B | 1×12mL |
| TMB Substrate | 1×9mL | Stop Solution | 1×6mL |
| Wash Buffer (30 × concentrate) | 1×20mL | Instruction manual | 1 |
Assay procedure summary
1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
8. Add 50µL Stop Solution. Read at 450nm immediately.
Test principle
The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Preferentially Expressed Antigen In Melanoma (PRAME). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Preferentially Expressed Antigen In Melanoma (PRAME). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Preferentially Expressed Antigen In Melanoma (PRAME), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Preferentially Expressed Antigen In Melanoma (PRAME) in the samples is then determined by comparing the O.D. of the samples to the standard curve.